A carregar...
Efficacy and safety of Gammaplex(®) 5% in children and adolescents with primary immunodeficiency diseases
This open‐label multi‐centre study evaluated Gammaplex(®) 5%, a human intravenous immunoglobulin (IVIG) 5% liquid, in 25 children and adolescent patients (aged 3–16 years) with primary immunodeficiency diseases (PIDs). Subjects received Gammaplex 5% (at doses of 300–800 mg/kg/infusion) for 12 months...
Na minha lista:
| Publicado no: | Clin Exp Immunol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4837242/ https://ncbi.nlm.nih.gov/pubmed/26696596 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cei.12760 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|